PI FINAL REVIEW

Feb 14, 2026 · 10 Qs × 10 marks · Every Room Accounted

🎯 COMPLETE PI TOPIC AUDIT EVERY ROOM

If this topic comes → what score? Green = exam-ready. Amber = partial. Red = would score 0-2.

SLOT 1: NUTRITION (P=1.00) — 1-3 Qs GUARANTEED
TopicScoreRisk
B12 deficiency8/10✅ Ready
B6 + INH7.5/10✅ Ready
B1 Thiamine5-6/10⚠️ Blueprint only, no recall
B3 Niacin4/10×0.10 suppressed — safety net via B6
B9 Folate4/10×0.25 suppressed — methyl trap in B12
Vitamin C5/10⚠️ Fe³⁺→Fe²⁺, scurvy basics
Vitamin D8.5/10✅ Ready
Vitamin A7.5/10✅ Ready
Vitamin K8/10✅ Ready
Vitamin E3/10⚠️ Minimal — spinocerebellar
Iron/Heme7/10✅ Ready
TPN8.5/10✅ Ready
Refeeding8.5/10✅ Ready
Nutritional neuro7/10✅ Ready
Malabsorption tests5/10⚠️ Embedded
Mediterranean diet1-2/10🚨 GAP → see Gap Fills
Iodine1-2/10🚨 GAP → see Gap Fills
Zinc1-2/10🚨 GAP → see Gap Fills
PEM1-2/10🚨 GAP → see Gap Fills
Obesity/BMI2/10🚨 GAP → see Gap Fills
Selenium3/10Low P — Keshan, deiodinase
SLOT 2: ANATOMY/PHYSIOLOGY (P=1.00) — 1-2 Qs
TopicScoreRisk
Coronary circulation7/10✅ In project
Cardiac conduction5/10⚠️ Blueprint only
Cerebral circulation5/10×0.10 suppressed
Spinal cord tracts7/10✅ Cross-section built
Nephron physiology7.5/10✅ Megacluster done
Portal system4/10⚠️ Partial
Temperature regulation3/10×0.10 suppressed
Neuroanatomy (functional)2/10🚨 GAP → see Gap Fills
GI arterial supply3/10Low P
SLOT 3: PHARMACOLOGY (P=1.00) — 1 Q
TopicScoreRisk
ACE inhibitors8/10✅ Strong
Metformin7/10✅ Ready
ARNi7/10✅ This session
SGLT2i8/10✅ Strong recall
Diuretics7/10✅ Embedded in nephron
Antiarrhythmics3/10×0.10 suppressed
Bedaquiline3/10×0.25 suppressed
Anticonvulsants1/10Low P — pre-final adjacent
Immunosuppressants1/10Low P
SLOT 4: PATHOPHYSIOLOGY (P=0.80)
TopicScoreRisk
DM pathophysiology5-6/10⚠️ Ominous octet unconfirmed
Septic shock8/10✅ Strong
Atherosclerosis7/10✅ In project
RAAS pathophysiology7/10✅ This session
Bilirubin metabolism2/10🚨 GAP → see Gap Fills
Hepatic encephalopathy2/10🚨 GAP → see Gap Fills
Thyroid pathophysiology2/10🚨 Could migrate from PIV
Heme synthesis/Porphyria3/10Low P
SLOT 5: PARASITOLOGY (P=0.75)
TopicScoreRisk
Strongyloides5/10⚠️ HTML built, no recall test
Leishmania5/10⚠️ In HTML tool
Wuchereria5/10⚠️ In HTML tool
Schistosoma5/10⚠️ In HTML tool
DIMAOE framework7/10✅ Universal framework
Echinococcus3/10×0.25 suppressed
Taenia solium3/10×0.10 suppressed
SLOT 6: ELECTROLYTE (P=0.50)
TopicScoreRisk
Hypokalemia7/10
Hyperkalemia7/10
Hyponatremia7/10✅ SIADH full
Calcium7/10
Drug-induced7/10
Magnesium4/10⚠️ Embedded only
SLOT 7: ACID-BASE (P=0.50)
TopicScoreRisk
Metabolic alkalosis8/10
HAGMA6/10⚠️ Ungraded
RTA types7/10
Respiratory acid-base2/10🚨 GAP
Mixed disorders2/10🚨 GAP
SLOT 8: INVESTIGATION (P=0.60)
TopicScoreRisk
PFTs4/10⚠️ HTML built, no recall → see Invest tab
CBNAAT3/10×0.25 suppressed
Bone marrow studies1/10🚨 → see Invest tab
LN biopsy1/10🚨 → see Invest tab
Flow cytometry1/10🚨 → see Invest tab
SLOT 9: POISONING (P=0.40)
TopicScoreRisk
OP poisoning6.5/10
Paracetamol4/10×0.10 suppressed
Lithium5/10⚠️ NDI embedded
Snake venom2/10🚨 → see Gap Fills
Scorpion1/10🚨 → see Scorpion tab
Copper/Wilson's2/10🚨 → see Gap Fills
SLOT 10: GENETICS/OTHER (P=0.20-0.30)
TopicScoreRisk
Gene therapy5/10⚠️ Ungraded
Clinical trials1/10🚨 → see Gap Fills
Pharmacogenomics3/10NAT2 in B6
Hypersensitivity rxns2/10🚨 → see Gap Fills
AMR / Antibiotic abuse1/10🚨 → see AMR tab
⚡ BOTTOM LINE
Quick 10 topics: ~20 topics ready at 7+/10 across Slots 1-7
Zero-risk topics: ~18 topics where you'd score 0-2 if ambushed
Biggest exposure: Slot 8 (Investigation 60% probability, 1/5 covered), Slot 9 (Poisoning), Slot 4 gaps (Bilirubin/HE)
🦂 SCORPION ENVENOMATION 10-MARK ANSWER

Pre-final PII loaded · Catalog: 2020, 2023 PII · Coastal Karnataka = HIGH environment · Could appear PI as basic science/poisoning

PARAGRAPH 1: Species & Epidemiology (2 marks)
Species: Mesobuthus tamulus (Indian Red Scorpion) — most lethal in India
Other: Palamnaeus swammerdami (Black Scorpion) — less toxic
Epidemiology: 1.2 million stings/year India, 3250 deaths. Rural agricultural, monsoon peak
Geography: Maharashtra (Konkan), Karnataka coast, Tamil Nadu, AP — Mangalore HIGH zone
Children: Higher mortality (small body mass = higher venom-to-weight ratio)
PARAGRAPH 2: Mechanism of Venom (3 marks — BASIC SCIENCE CORE)
Venom component: Low molecular weight neurotoxic peptides (α-toxins)
Primary target: Voltage-gated sodium channels (VGSCs) → delayed inactivation → prolonged depolarization
Also activates: Calcium channels of neuromuscular system
Net effect: Massive release of endogenous catecholamines (epinephrine + norepinephrine) + acetylcholine
Result: "AUTONOMIC STORM" — simultaneous sympathetic + parasympathetic overdrive
⚡ KEY MECHANISM TO REMEMBER
Venom → Na⁺ channel stays OPEN → nerve keeps firing → massive catecholamine surge → autonomic storm
Think: "Scorpion keeps the door open → storm rushes in"
PARAGRAPH 3: Clinical Features — Biphasic (2 marks)
PhaseDriven ByFeatures
Early SympatheticCatecholamine surgeTachycardia, hypertension, sweating, piloerection, mydriasis, hyperglycemia
ParasympatheticACh releaseBradycardia, hypotension, salivation, lacrimation, vomiting, priapism
CRITICALBothAcute pulmonary edema (#1 killer) — both cardiogenic (myocarditis from catecholamine) + non-cardiogenic (capillary leak)
CardiacDirect myotoxicityMyocarditis, LV dysfunction, arrhythmias
NeuroNeurotoxinEncephalopathy, seizures (children), rotary eye movements
Local: Intense burning pain at sting site with minimal swelling (unlike snake bite)
Grading: Grade I (local) → II (systemic mild) → III (autonomic/neuromuscular) → IV (combined = ICU)
PARAGRAPH 4: Treatment — PRAZOSIN IS THE ANSWER (2 marks)
PRAZOSIN (α₁-blocker) — revolutionized management since 1983 (Bawaskar & Bawaskar)
Mechanism: Post-synaptic α₁ blockade → reduces preload + afterload → counters catecholamine-induced HTN + pulmonary edema
Dose Adult: 0.5 mg oral, repeat q3h PRN; Children: 30 μg/kg/dose
⚠️ First-dose hypotension: Monitor BP. Keep IV fluids ready.
Anti-Scorpion Venom Serum (AScVS): Equine-derived F(ab')₂ fragments. Faster recovery (10h vs 16-42h with prazosin alone). Combined SAV + prazosin is optimal for severe cases.
Supportive: Dobutamine for myocardial dysfunction. Nitroprusside/nitroglycerin for severe HTN + pulmonary edema. Mechanical ventilation PRN.
⚠️ WHAT NOT TO GIVE
NO steroids + antihistamines as primary treatment → higher mortality in children (Mahadevan).
NO atropine routinely → blocks parasympathetic but worsens sympathetic storm (tachycardia, HTN).
Epinephrine CAUTION → risk of ventricular arrhythmia on catecholamine-injured myocardium.
PARAGRAPH 5: Prognosis & Indian Context (1 mark)
Mortality: 1-10.7% in India. Higher in children, late presentation (>6h), irrational therapy
Good prognostic sign: Children have healthy myocardium → should recover with proper Rx
Poor prognostic factors: Metabolic acidosis, myocarditis, priapism, encephalopathy, pulmonary edema
Mangalore context: Coastal agricultural belt. Monsoon presentations. Rural delay = main mortality driver.
5 RETENTION ANCHORS
Mesobuthus tamulus = Indian Red Scorpion = most lethal in India
"Scorpion keeps Na⁺ door open" → autonomic storm → catecholamine surge
Pulmonary edema = #1 killer (cardiogenic + non-cardiogenic)
PRAZOSIN (α₁-blocker) = game-changer. Bawaskar 1983.
NO steroids/antihistamines = higher mortality in children
💊 ANTIMICROBIAL RESISTANCE & STEWARDSHIP 10-MARK ANSWER

PI family: ESBL (2020), GNB (2021) · Pre-final PII: Antibiotic abuse, NDM-1 · PII: Stewardship (2022) · India = world's largest antibiotic consumer

PARAGRAPH 1: Definition & Magnitude (2 marks)
AMR: Microorganisms evolve to resist drugs designed to kill them → treatment failure
India burden: World's LARGEST antibiotic consumer — 12.9 billion units/year (China 10B, USA 6.8B)
MRSA: Rose from 29% (2008) → 47% (2014) in India. Countries with stewardship = declining.
NDM-1: New Delhi Metallo-beta-lactamase — discovered 2010 (India/Pakistan/UK). Carbapenem resistance in Gram-negatives.
Colistin resistance: mcr-1 gene identified — threatens the LAST resort antibiotic
PARAGRAPH 2: Mechanisms of Resistance (3 marks — BASIC SCIENCE)
MechanismHow It WorksExample
Enzymatic degradationEnzyme breaks down antibiotic before reaching targetβ-lactamases (ESBL, AmpC, MBL/NDM-1) → hydrolyze β-lactams
Target modificationAltered binding site → antibiotic can't attachPBP2a (mecA gene) in MRSA → methicillin can't bind PBP
Efflux pumpsActively pump antibiotic OUT of bacterial cellPseudomonas → fluoroquinolone/tetracycline resistance
Porin lossOuter membrane channels close → drug can't enterOprD loss in Pseudomonas → carbapenem resistance
Target bypassAlternative metabolic pathwayVanA in Enterococcus → D-Ala-D-Lac instead of D-Ala-D-Ala → vancomycin can't bind
Spread mechanisms: Plasmids (conjugation), transposons, integrons, transformation, transduction
Mobile genetic elements (MGEs) allow horizontal gene transfer between unrelated bacteria — cross-species spread
PARAGRAPH 3: ESKAPE Pathogens (2 marks)
ESKAPE = WHO priority pathogens threatening treatment:
LetterOrganismKey Resistance
EEnterococcus faeciumVRE (vancomycin-resistant)
SStaphylococcus aureusMRSA (mecA → PBP2a)
KKlebsiella pneumoniaeESBL + carbapenemase (KPC, NDM)
AAcinetobacter baumanniiMDR/XDR — ICU nightmare
PPseudomonas aeruginosaIntrinsic resistance + efflux + porin loss
EEnterobacter speciesAmpC inducible + ESBL
PARAGRAPH 4: Antimicrobial Stewardship (2 marks)
Definition: Systematic approach to optimize antimicrobial use — right drug, right dose, right duration
WHO AWARE classification:
  Access: First-line, widely available (amoxicillin, cotrimoxazole)
  Watch: Higher resistance potential, limited use (fluoroquinolones, cephalosporins)
  Reserve: Last resort (colistin, linezolid, carbapenems) — use ONLY when all else fails
Key interventions: Prescription audit, antibiotic timeout, de-escalation after culture, dose optimization, restrict OTC sale
ICMR AMSP: Pilot in 20 tertiary hospitals → 22-36% reduction in antibiotic use
PARAGRAPH 5: India's National Action Plan (1 mark)
NAP-AMR 1.0: Launched 2017 — 6 strategic priorities (aligned with WHO GAP + India-specific 6th priority on leadership)
NAP-AMR 2.0: Launched Nov 2025 (2025-2029) — One Health approach
One Health: Human + Animal + Environment — India banned colistin as growth promoter in poultry
ICMR AMRSN: AMR Surveillance Network since 2013 — 30 sites in 24 states
India-specific challenges: OTC antibiotic sale, unregulated animal sector, weak state-level enforcement, health = state subject
5 RETENTION ANCHORS
India = #1 antibiotic consumer — 12.9 billion units/year
5 mechanisms: Enzyme (ESBL), Target change (PBP2a), Efflux, Porin loss, Bypass (VanA)
ESKAPE = E.faecium, S.aureus, K.pneumoniae, A.baumannii, P.aeruginosa, Enterobacter
WHO AWARE: Access → Watch → Reserve (colistin = last resort under threat)
NAP-AMR 2.0 (2025) — One Health approach — ICMR AMSP in 20 hospitals
🔬 INVESTIGATION SLOT GAPS P=0.60
PFTs — Pulmonary Function Tests

Pre-final loaded · Catalog: 2016, 2019 PI · 7yr gap = DUE · HTML drill built

ParameterObstructiveRestrictive
FEV₁↓↓ (more reduced)
FVC↓ or Normal↓↓ (more reduced)
FEV₁/FVC ratio< 0.70 (REDUCED)Normal or ↑
TLC↑ (hyperinflation)↓ (small lungs)
RV↑ (air trapping)
RV/TLCNormal
DLCO↓ in emphysema, Normal in asthma↓ in ILD, Normal in NM disease
⚡ DIRECTION TRAP
FEV₁/FVC is the KEY discriminator:
LOW ratio = Obstructive (air can't get OUT → think COPD, asthma)
Normal/High ratio = Restrictive (lungs can't EXPAND → think ILD, NM disease)
Anchor: "O-bstruction = O-ut problem = LOW ratio"
Obstructive diseases: COPD, Asthma, Bronchiectasis, CF
Restrictive diseases: ILD/pulmonary fibrosis, neuromuscular (MG, GBS), chest wall (kyphoscoliosis), obesity
Reversibility test: Give salbutamol → FEV₁ ↑ by ≥12% AND ≥200mL = reversible = asthma
DLCO utility: Distinguishes emphysema (↓ — alveolar destruction) from asthma (normal — airways only)
Flow-volume loops: Obstructive = scooped out expiratory limb. Fixed upper airway = flattened both limbs. Variable extrathoracic = flattened inspiratory.
India: COPD from biomass fuel > smoking. Restrictive from TB sequelae, silicosis (stone workers), byssinosis (cotton)
BONE MARROW STUDIES — Minimum Viable Answer

Catalog: 2022 PI · Low P (×0.10 era proximity)

Indications: Unexplained cytopenias, staging lymphoma/leukemia, fever of unknown origin, storage disorders, granulomas (TB/sarcoid)
Types: Aspiration (cell morphology, differential count, iron stores) vs Trephine biopsy (architecture, cellularity, fibrosis)
Site: Posterior superior iliac spine (PSIS) — adults. Anterior tibia — children <2y
M:E ratio: Normal 2-4:1. Reversed in megaloblastic anemia, ITP. Increased in CML.
Special stains: Prussian blue (iron stores/ring sideroblasts), reticulin (fibrosis), Congo red (amyloid), PAS (erythroleukemia)
India: Kala-azar (Leishmania amastigotes in marrow), HIV staging, TB granulomas, megaloblastic (B12 common in vegetarians)
LYMPH NODE BIOPSY — Minimum Viable Answer

Catalog: 2023 PI

Indications: Persistent lymphadenopathy >2 weeks, >2cm, hard/fixed, supraclavicular (always biopsy), suspected lymphoma/metastasis
Types: Excisional (GOLD STANDARD — architecture preserved) > Core needle > FNAC (cytology only, misses architecture)
Why excisional: Lymphoma diagnosis REQUIRES architecture (follicular vs diffuse pattern). FNAC cannot classify lymphoma subtype.
Special studies: IHC (CD markers), flow cytometry (lymphoma subtyping), culture (TB), PCR (EBV, CMV)
India: TB lymphadenitis (#1 cause peripheral LAP in India), reactive to chronic infections, NHL, Kikuchi disease
FLOW CYTOMETRY — Minimum Viable Answer

Catalog: 2020 PI · Pre-final PIV

Principle: Cells in suspension pass through laser beam → scatter light + emit fluorescence from tagged antibodies → detects surface/intracellular markers
Forward scatter: Cell SIZE. Side scatter: Cell GRANULARITY/complexity.
Applications: Leukemia/lymphoma immunophenotyping (CD markers), HIV CD4 count, PNH (CD55/CD59 loss), minimal residual disease (MRD)
CD markers: CD3 (T-cell), CD4 (Helper T), CD8 (Cytotoxic T), CD19/CD20 (B-cell), CD34 (stem cell), CD56 (NK cell)
India: HIV CD4 monitoring (threshold <350 for ART initiation per NACO), ALL/AML classification, PNH diagnosis
5 RETENTION ANCHORS — INVESTIGATIONS
FEV₁/FVC < 0.70 = Obstructive ("O = Out = Low")
DLCO separates emphysema (↓) from asthma (normal)
Excisional biopsy = gold standard for LN (architecture for lymphoma)
Flow cytometry: laser + fluorescent antibodies → CD markers → leukemia subtyping
Bone marrow: PSIS site, Prussian blue for iron, M:E ratio 2-4:1 normal
⚡ QUICK 10 TOPICS — Already Strong 7+/10

These just need a memory jog, not re-teaching. Key pitfall per topic only.

NUTRITION QUICK 10s
B12 (8/10)MMA not "malonic acid" · Neuro without anemia = 28% · Schilling test
B6+INH (7.5/10)10mg/day prophylaxis · Hydrazone · Cycloserine NOT cyclophosphamide
Vitamin D (8.5/10)Parafollicular = Calcitonin · Chief cells = PTH · 1,25(OH)₂D₃ active
Vitamin A (7.5/10)MEASLES not mumps · Bitot's spots · Teratogenic · Night blindness first
Vitamin K (8/10)γ-carboxyglutamate · Factors II,VII,IX,X · Warfarin bridging protects
Iron/Heme (7/10)Hepcidin ↑ = ferroportin degraded = iron trapped · Anemia of chronic disease
TPN (8.5/10)Soybean oil standard lipid · Cycle 12-16hr · Central line (osmolality >900)
Refeeding (8.5/10)BMI <16 · PO₄ = hallmark killer · Start 10 kcal/kg/day · K⁺, Mg²⁺, thiamine
ANATOMY/PHYSIOLOGY QUICK 10s
Nephron (7.5/10)PCT: bulk reabsorption + SGLT2 · LOH: countercurrent · DCT: Ca²⁺ (thiazide) · CD: ADH + aldosterone
Spinal cord (7/10)DCML = ipsilateral proprioception · STT = contralateral pain/temp · SACD: B12
Coronary (7/10)LAD = "widow maker" · RCA = SA/AV node (dominant 85%) · LCx = lateral wall
PHARMACOLOGY QUICK 10s
ACEi (8/10)Cr ↑ 30% acceptable · Triple whammy · Bradykinin → cough/angioedema · Contraindicated bilateral RAS
SGLT2i (8/10)4-pillar: HF/DM/CKD/CV · Tubuloglomerular feedback · Euglycemic DKA risk · Empagliflozin/Dapagliflozin
ARNi (7/10)Sacubitril-Valsartan · PARADIGM-HF · 36h washout from ACEi · Neprilysin → NPS preserved
Metformin (7/10)AMPK activation · Pleiotropic: ↓hepatic glucose, ↑insulin sensitivity · Lactic acidosis with eGFR <30 · No weight gain
PATHOPHYSIOLOGY QUICK 10s
Septic shock (8/10)PAMPs → TLR → NF-κB → TNF-α/IL-1/IL-6 → vasodilation + capillary leak · Norepinephrine first-line
Atherosclerosis (7/10)Endothelial injury → LDL oxidation → foam cells → fatty streak → fibrous cap → rupture → thrombus
RAAS (7/10)Renin → Ang I → ACE → Ang II → 6 effects (vasoconstriction, aldosterone, ADH, thirst, SNS, remodeling)
ELECTROLYTE/ACID-BASE QUICK 10s
Metabolic alkalosis (8/10)Saline-responsive (vomiting, diuretics) vs Saline-resistant (Conn's, Cushing's) · Urine Cl⁻ <20 = responsive
RTA types (7/10)RTA1: distal, urine pH >5.5, hypoK · RTA2: proximal, urine pH <5.5 (can acidify), hypoK · RTA4: hypoaldo, hyperK, pH <5.5
OP Poisoning (6.5/10)AChE inhibition → DUMBELS + nicotinic · Atropine (muscarinic) + Pralidoxime (reactivates AChE) · Intermediate syndrome Day 1-4
⚡ PERSISTENT DIRECTION INVERSIONS — WATCH LIST
Trap❌ Wrong✅ Correct
Conn's K⁺HyperkalemiaHypoK (aldosterone pushes K⁺ OUT)
DCT Ca²⁺ + ThiazideWastes calciumThiazide SAVES Ca²⁺ (reabsorbs)
V2 receptorOn collecting duct lumenOn BASOLATERAL side of CD
D-xylose testNormal = mucosalNormal = PANCREATIC cause
Parafollicular cellsPTHCALCITONIN (C-cells = C-alcitonin)
MEASLES + Vit AMumpsMEASLES (M-easles = M-acular involvement)
🚨 GAP FILL — Minimum Viable Answers 0→4-5/10 IF AMBUSHED

These aren't full answers. They're enough to NOT score zero.

🫒 MEDITERRANEAN DIET
Definition: Plant-based diet emphasizing olive oil, fruits, vegetables, legumes, whole grains, fish, moderate wine. Low red meat.
PREDIMED trial (2013): Mediterranean + extra-virgin olive oil vs low-fat → 30% reduction in major CV events
Mechanism: Anti-inflammatory (↓CRP, ↓IL-6), anti-oxidant (polyphenols), ↓LDL oxidation, improves endothelial function
Benefits: CVD ↓30%, T2DM prevention, cognitive decline protection, cancer risk ↓
Indian context: Parallels with traditional Indian diets (plant-heavy, turmeric/anti-inflammatory), but Indian diet higher in refined carbs/oils
🧂 IODINE DEFICIENCY/EXCESS
Physiology: Iodine → thyroid → T3/T4 synthesis. Trapped by NIS (Sodium-Iodide Symporter) on basolateral membrane
Deficiency: Goiter (↓T4 → ↑TSH → thyroid hyperplasia), cretinism (neurological: deaf-mutism, mental retardation; myxedematous: short stature)
Wolff-Chaikoff effect: EXCESS iodine → temporary INHIBITION of organification → transient hypothyroidism. Escape occurs normally.
Jod-Basedow: Excess iodine → hyperthyroidism in nodular goiter (autonomous nodules)
Mangalore paradox: Coastal = iodine sufficient, yet thyroid cancer + Hashimoto's MORE common. Excess iodine → autoimmune thyroiditis.
India: National Iodine Deficiency Disorders Control Programme (NIDDCP). Mandatory salt iodization. RDA 150 μg/day adult.
🥩 PEM — Kwashiorkor vs Marasmus
FeatureKwashiorkorMarasmus
DeficiencyProtein (adequate calories)Total calorie (protein + energy)
EdemaYES — pedal, pittingNO
Weight60-80% expected<60% expected
AppearanceMoon face, distended abdomen, flaky paint dermatosis, flag sign hairWasted, "skin and bones", old man face, baggy pants buttocks
AlbuminVery lowLow but relatively preserved
Fatty liverYES (↓VLDL synthesis)NO
ImmuneBoth severely impairedBoth severely impaired
India: ICDS (Integrated Child Development Scheme), mid-day meals, WHO ORS + zinc for diarrheal complications, WHO growth charts
Management: Stabilize (hypothermia, hypoglycemia, infection), then cautious refeeding → rehabilitation → follow-up (10 steps WHO)
🐍 SNAKE VENOM — Basic Science
"Big Four" India: Russell's Viper, Common Krait, Indian Cobra, Saw-Scaled Viper
SnakeVenom TypeKey Effect
Russell's ViperHemotoxic + vasculotoxicDIC, AKI, capillary leak, bleeding
Common KraitNeurotoxic (pre-synaptic)Descending paralysis (ptosis → respiratory failure). Minimal local signs.
Indian CobraNeurotoxic (post-synaptic)Local necrosis + neurotoxicity. Reversible with neostigmine.
Saw-Scaled ViperHemotoxicEchis = ecchymosis. DIC. Most bites in India.
Polyvalent ASV: Only treatment. Dose: 10 vials IV over 1hr. Repeat if clotting not restored by 6h (20WBCT).
20WBCT: 20-min Whole Blood Clotting Test — bedside test. Non-clotting = viper envenomation. Repeat 6-hourly.
Mangalore: Coastal agricultural belt. Krait nocturnal bites in rural sleeping. Monsoon peak. ASV at every PHC per NHSRC.
🧬 BILIRUBIN METABOLISM — Quick Framework
Source: 80% heme (senescent RBCs in spleen) → Biliverdin → Unconjugated Bilirubin (UCB, indirect)
Transport: UCB bound to albumin → liver (can't filter in kidney = no urine bilirubin)
Conjugation: Hepatocyte: UDP-glucuronosyltransferase (UGT1A1) → Conjugated Bilirubin (CB, direct, water-soluble)
Excretion: CB → bile → gut → urobilinogen (some reabsorbed = enterohepatic circulation, some → stercobilin in stool, some → urobilinogen in urine)
Unconjugated ↑: Hemolysis (Gilbert's = UGT1A1 ↓, Crigler-Najjar)
Conjugated ↑: Obstruction (gallstones, tumor), hepatocellular (Dubin-Johnson = MRP2 defect, Rotor)
🧠 HEPATIC ENCEPHALOPATHY — Quick Framework
Pathogenesis: Liver failure → ↓ammonia clearance → NH₃ crosses BBB → astrocyte: glutamine synthetase converts glutamate + NH₃ → glutamine → osmotic swelling → cerebral edema
Precipitants: GI bleed (#1), infection/SBP, constipation, drugs (sedatives, diuretics), electrolyte imbalance (hypoK → ↑renal NH₃ production)
West Haven Grades: 0 (minimal/subclinical) → I (mood change, tremor) → II (lethargy, asterixis) → III (somnolent, confused) → IV (coma)
Treatment: Lactulose (acidifies gut → NH₃→NH₄⁺ = trapped = excreted) · Rifaximin (↓gut NH₃-producing bacteria) · Treat precipitant · Protein NOT restricted long-term (branched-chain amino acids preferred)
India: Alcohol-related cirrhosis common (Karnataka toddy/arrack). Hepatitis B/C in blood transfusion era.
🔬 CLINICAL TRIALS — Quick Framework
Phases: Phase I (safety, healthy volunteers, 20-80) → Phase II (efficacy, small patient group, 100-300) → Phase III (large RCT, 1000-3000, vs standard) → Phase IV (post-marketing surveillance)
RCT: Gold standard. Randomized, controlled, (ideally double-)blinded. Minimizes bias.
Key concepts: ITT (intention-to-treat) vs Per-protocol. NNT (number needed to treat). p-value <0.05. Confidence interval.
Ethics: Informed consent, IRB/Ethics committee approval, Declaration of Helsinki, ICMR ethical guidelines 2017
India: CDSCO regulation. New Drugs and Clinical Trials Rules 2019. Compensate injury. Audio-visual consent for illiterate.
🧪 ZINC DEFICIENCY
Functions: >300 enzyme cofactor, DNA/RNA synthesis, immune function, wound healing, taste/smell
Deficiency features: Acrodermatitis enteropathica (perioral + acral rash), diarrhea, alopecia, growth retardation, hypogonadism, impaired immunity
Causes: Malnutrition, malabsorption, alcoholism, sickle cell, TPN without supplementation
Excess zinc → copper depletion → myelopathy mimicking SACD (subacute combined degeneration) — diagnostic trap!
India: WHO recommends zinc + ORS for childhood diarrhea (20mg/day × 14 days). Zinc deficiency widespread in malnourished children.
⚡ HYPERSENSITIVITY REACTIONS
TypeMechanismTimingExamples
I — ImmediateIgE → mast cell degranulationMinutesAnaphylaxis, asthma, urticaria, hay fever
II — CytotoxicIgG/IgM vs cell surface antigenHoursABO transfusion rxn, AIHA, Goodpasture, Rh HDN
III — Immune complexAg-Ab complexes → complement → tissue damageHours-daysSerum sickness, SLE nephritis, post-strep GN, Arthus
IV — DelayedT-cell mediated48-72hTB skin test, contact dermatitis, graft rejection, granulomas
Type II subtypes: IIa = cytotoxic (AIHA), IIb = stimulatory (Graves' — TSI), IIc = blocking (MG — anti-AChR)
🧫 COPPER / WILSON'S DISEASE
Wilson's: AR mutation in ATP7B gene → impaired copper excretion into bile → copper accumulates in liver, brain, cornea
Triad: Liver disease (hepatitis → cirrhosis) + Neuropsychiatric (tremor, dystonia, parkinsonism, behavioral) + Kayser-Fleischer rings (copper in Descemet's membrane)
Diagnosis: ↓Ceruloplasmin (<20 mg/dL), ↑24hr urine copper (>100μg/day), ↑hepatic copper on biopsy, KF rings on slit lamp
Treatment: D-Penicillamine (chelation — first line) or Trientine (if intolerant). Zinc acetate (blocks intestinal absorption — maintenance). Liver transplant if fulminant.
India: AR — consanguinity prevalent in some communities → higher incidence. Screen siblings. Lifelong treatment.
🏋️ OBESITY / BMI — Indian Thresholds
WHO BMI: Overweight ≥25, Obese ≥30. BUT Indian thresholds LOWER: Overweight ≥23, Obese ≥25 (Asian criteria)
Waist circumference: Indian cutoffs: Men ≥90 cm, Women ≥80 cm (vs WHO 102/88)
"Thin-fat Indian": Normal BMI but high visceral fat, insulin resistance, metabolic syndrome — South Asian phenotype
Complications: T2DM, CVD, OSA, NAFLD, OA, cancer (endometrial, colon, breast)
India burden: ICMR-INDIAB: diabetes prevalence 11.4%. Urban epidemic. NFHS-5: 24% women, 23% men overweight.
5 RETENTION ANCHORS — GAP FILLS
PREDIMED = Mediterranean diet = 30% CV reduction
Wolff-Chaikoff = excess iodine → blocks T4 (opposite of what you'd expect)
Kwashiorkor = Edema + Fatty liver (protein deficit → ↓VLDL → fat stays in liver)
Krait = PRE-synaptic (irreversible) vs Cobra = POST-synaptic (neostigmine helps)
Bilirubin: UCB = bound to albumin (no urine) → UGT1A1 conjugates → CB = water-soluble (urine dark)